BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25762434)

  • 1. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence.
    Alshalalfa M; Crisan A; Vergara IA; Ghadessi M; Buerki C; Erho N; Yousefi K; Sierocinski T; Haddad Z; Black PC; Karnes RJ; Jenkins RB; Davicioni E
    BJU Int; 2015 Oct; 116(4):556-67. PubMed ID: 25762434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
    Stephenson AJ; Kattan MW; Eastham JA; Dotan ZA; Bianco FJ; Lilja H; Scardino PT
    J Clin Oncol; 2006 Aug; 24(24):3973-8. PubMed ID: 16921049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
    Schroeck FR; Sun L; Freedland SJ; Jayachandran J; Robertson CN; Moul JW
    Prostate Cancer Prostatic Dis; 2008; 11(4):371-6. PubMed ID: 18427570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
    Simmons MN; Stephenson AJ; Klein EA
    Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
    Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
    Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.